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1 Introduction 
 
1.1 Physiological basis and analyses of heart rate variability 
 
Heart rate variability (HRV) analysis has become a popular non-invasive tool for 
investigating activity of cardiac autonomic nervous system. HRV analysis is more 
widely used in research than in medical practice. The autonomic nervous system 
regulates visceral functions through the sympathetic and parasympathetic branches. In 
the cardiovascular system this nonstationary balance results in the fluctuation between 
intervals of consecutive heart beats, so called heart rate variability. (1-3) 
 
Cardiac intrinsic automaticity of various pacemaker tissues is under the control of the 
autonomic nervous system (ANS). The parasympathetic influence is mediated via 
acetylcholine by the vagus nerve. Acetylcholine activates muscarinic receptors. The 
sympathetic influence is mediated via noradrenalin released by sympathetic nerves, and 
adrenalin released by adrenal medulla. Both noradrenalin and adrenalin activate both α- 
and β-adrenergic receptors. Under resting conditions vagal tone dominates. Heart rate 
variability reflects the function of ANS, especially parasympathetic division. Vasomotor 
and respiratory centers in the central nervous system and humoral factors circulating in 
blood affect also heart rate variability. (4) 
 
Traditional methods in analyzing heart rate variability are time domain analysis and 
frequency domain analysis. In addition, nonlinear methods of analysis are used. They 
are more recently developed and interpretation of them is more complicated, i.e. there is 
not a consensus how they reflect the function of ANS. Ectopic and artefactal beat 
corrections of RR interval data are essential prior to HRV analysis. Heart rate variability 
analyzing software includes usually an automatic RR interval correction but the data 
should be also inspected visually to evaluate validity of the automatic correction. (3) 
 
2 
 
In time domain analysis each QRS complex is detected in a continuous ECG record, and 
the RR intervals or the so called normal-to-normal (NN) intervals (that is, all intervals 
between adjacent QRS complexes resulting from sinus node depolarizations) or the 
instantaneous heart rate is determined. The simple time domain variables that can be 
calculated include for example the mean RR interval and the mean heart rate. Also 
statistical time domain measures can be calculated. Those are for instance the standard 
deviation of the NN intervals (SDNN), the square root of the mean squared differences 
of successive NN intervals (RMSSD), the number of interval differences of successive 
NN intervals greater than 50 ms (NN50), and the proportion derived by dividing NN50 
by the total number of NN intervals (pNN50). (4) 
 
In frequency domain analysis the power spectral density is calculated. Three main 
spectral components are distinguished in short-term recordings: very low frequency 
(VLF, 0-0.04 Hz), low frequency (LF, 0.04-0.15 Hz) and high frequency (HF, 0.15-0.4 
Hz) component. VLF, LF and HF can be measured in absolute values of power 
(milliseconds squared). LF and HF can also be measured in normalized units, which 
present the relative value of each component. In long-term recordings there is possible 
to analyze also ultra low frequency component in the spectrum. (4) Detrended 
fluctuation analysis (DFA) and Poincare plot are some of many nonlinear methods in 
HRV analyses (2).  
 
The parasympathetic activity is the major contributor to the HF component. Also 
RMSSD, NN50 and pNN50 reflects vagal modulation. There is a disagreement if the LF 
component reflects sympathetic activity or both sympathetic and parasympathetic 
activity. (2,4) LF/HF-ratio represents sympathovagal balance and interaction (2).  SD1 
of Poincare plot represents parasympathetic activity (5).  Alpha 1 of DFA has been 
reported to correlate with LF:HF ratio related to ANS function tests (cold face 
immersion and cold hand immersion) (6).  
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1.2 The effect of gender, age, physical fitness and illnesses on heart rate 
variability 
 
Several factors affect heart rate variability, such as age and gender (7). Heart rate 
variability declines with age till 80 years (8-10) and after that HRV indices reflecting 
vagal tone increases again (11). The results of HRV differences between genders are 
somewhat conflicting (7,12,13). This difference between genders diminishes with age 
(12). In addition, both psychological and physical stress decreases the HRV indices 
reflecting parasympathetic activity (14,15). Heart rate variability has also circadian 
profile. Parameters reflecting vagal tone are higher during the night than during the day. 
(7) 
 
The importance of diabetes in the epidemiology of cardiovascular diseases cannot be 
overemphasized (16). Cardiovascular autonomic neuropathy (CAN) is a frequent 
complication of diabetes mellitus, which is associated with increased morbidity and 
mortality. It involves both the parasympathetic and sympathetic nervous system. CAN 
is usually diagnosed with dynamic tests involving measurement of heart rate and/or 
blood pressure. CAN is associated with poor prognosis. It is a complication of both type 
1 and type 2 diabetes. (17,18) It is also associated with silent ischemia (17). CAN is 
found to be associated with modifiable risk factors (central fat distribution, 
hypertension, dyslipidemia, worse diabetes control, and smoking, and with the other 
microvascular complications of diabetes) (19).  
 
In many studies heart rate variability has been decreased in diabetics with autonomic 
neuropathy as well as in those without (1,20-23). Reduced HRV has been reported 
already in children with type 1 diabetes (24). It also seems that in insulin-dependent 
diabetes patients high frequency power i.e. vagal tone of cardiac ANS decreases with 
the increasing duration of diabetes (25). It has been reported that decrease of LF power 
and HF power highly correlates with CAN severity. CAN is also reported to correlate in 
stepwise regression with age, retinopathy, nephropathy, bladder dysfunction, erectile 
dysfunction, peripheral neuropathy and hypertension. (26) One study reported that in 
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type 1 diabetics, high serum lipoprotein levels were related to a lower HRV while in 
healthy controls and chronic stable angina patients serum lipoprotein levels did not 
associate with lower HRV (27). It has been reported that in active standing and handgrip 
tests, which are used for testing ANS function, the change in alpha 1 of DFA was 
smaller in type 1 diabetes patients than in healthy controls, while other HRV parameters 
did not differ significantly between groups. DFA of nonlinear methods might be 
sensitive tool for detecting ANS dysfunction in early phase. (28) 
 
Many studies have related the imbalance of the autonomic nervous system as assessed 
by HRV to several pathophysiological conditions, particularly in the setting of 
cardiovascular disease. Sudden death, coronary artery disease, heart failure, or merely 
cardiovascular risk factors (smoking, diabetes, hyperlipidemia, and hypertension) are 
the best-known clinical circumstances that can affect and/or be affected by the 
autonomic nervous system. (2) Heart rate variability is decreased and sympathetic tone 
increased after myocardial infarction (3). HRV is also decreased in chronic angina 
patients (29). Decreased activity of parasympathetic nervous system is related to a 
greater risk for cardiac event (30). The lower HRV is also associated with progression 
of calcification of coronary arteries in adults with and without type 1 diabetes (31). 
Smoking decreases HRV acutely and it also has an effect on baseline HRV (32,33). 
Body mass index (BMI) does not correlate with HRV (34,35). 
 
There is a connection with physical fitness and cardiac ANS function. Regular exercise 
increases vagal tone and decreases resting heart rate. However, it is somewhat 
conflicting whether regular aerobic exercise increases heart rate variability. (30) It is 
controversial how a single bout of exercise affects heart rate variability during the next 
24 hours. In one research exercise at approximately 65% of maximal oxygen uptake 
increased the HRV indices reflecting parasympathetic tone (36) while in three other 
researches moderate and heavy aerobic exercise decreased the overall HRV and  indices 
reflecting parasympathetic tone (9,37,38). Endurance training also seems to increase 
high frequency power at nighttime (37-39). Also, one study found that in overtrained 
athletes parasympathetic cardiac modulation was slightly diminished after awakening 
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compared to control athletes. However, there was no difference in HRV between 
overtrained and control athletes during sleep. (40)  
 
1.3 Type 1 diabetes and aerobic capacity 
 
In several studies type 1 diabetic subjects has been reported to have lower aerobic 
capacity than healthy subjects (28,41-45). However, there are also studies which have 
reported similar maximal oxygen uptake in similarly trained diabetic and non-diabetic 
subjects (46,47). One study reported that type 1 diabetic athletes with optimal glycemic 
control had significantly higher aerobic capacity than type 1 diabetic athletes with poor 
glycemic control. Glycemic control possibly can have an independent effect on aerobic 
capacity. (48) Regular exercise and higher aerobic capacity is associated with enhanced 
vagal modulation (30,49) so type 1 diabetes patients who are at risk of CAN or who 
have reduced HRV can benefit from regular exercise and good aerobic capacity because 
decreased parasympathetic activity is related to a higher risk for cardiac event (30). 
 
2 Objectives 
 
Heart rate variability has been studied in type 1 diabetes patients during their normal 
daily activities and at rest but not during long term recovery from maximal 
performance. HRV in type 1 diabetes patients has also been studied during ANS 
function tests as deep breathing, active standing and handgrip tests. The aim of this 
study was to examine differences in heart rate variability during 48-hour recovery from 
incremental cycle ergometer test between type 1 diabetes patients and healthy controls. 
Heart rate variability was recorded for 24-48 hours after maximal exercise. The study 
paid special attention to HRV during nighttime and the first hours after exercise. This 
study aimed to examine the associations of HRV during recovery with maximal oxygen 
uptake and with diabetes. We also studied HRV after 6-12 months training intervention. 
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Study questions: 
 
1. Is there a difference in HRV during 48-hour recovery between type 1 diabetes 
patients and healthy controls? 
 
2. Is the potential difference in heart rate variability during recovery between type 
1 diabetes patients and healthy controls associated with maximal oxygen uptake 
and/or diabetes? 
 
3. Does heart rate variability during recovery in type 1 diabetes patients and 
healthy controls increase with regular exercise?  
 
3 Subjects and methods 
 
3.1 Subjects 
 
The study was performed in University of Helsinki, Department of Sports and Exercise 
Medicine. There were 29 subjects, all of them were men, aged 25-46 years. Subject 
characteristics are presented in Table 1 and Table 2. Type 1 diabetes patients (n=13) 
were normo- or microalbuminuric and they did not have autonomic neuropathy or, at 
the most, were classified to have borderline ANS dysfunction. Healthy controls (n=16) 
were age-, gender-, anthropometry- and self-reported physical activity matched. 
Smoking and snuff using subjects were excluded from the study.  
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Table 1. Subject characteristics in baseline measurements. 
  T1D patients Healthy controls P 
Number of subjects 13   
  
16 
 
  NS 
Age (years) 32.3 ± 6 32.8 ± 6.3 NS 
Height (cm) 178.6 ± 8.3 181.3 ± 4.3 NS 
Weight (kg) 77.8 ± 10.5 83.3 ± 12.1 NS 
BMI (kg/m²) 24.3 ± 2.3 25.3 ± 3.5 NS 
LTPA (min/week) 281 ± 140 328 ± 177  NS  
Duration of diabetes (years) 10.6 ± 6.2        
HbA1c (%) (n=12) 7.2 ± 0.7        
VO2max (ml/kg/min) 36.9 ± 4.7 42.9 ± 9.2 0.036 
VO2max (l/min) 2.88 ± 0.58 3.49 ± 0.45 0.007 
T1D=type 1 diabetes, BMI=body mass index, LTPA=leisure-time physical activity, 
HbA1c=glycosylated hemoglobin, VO2max=maximal oxygen uptake, NS=non-
significant. 
 
Table 2. Subject characteristics in measurements after training intervention. 
  T1D patients Healthy controls P 
Number of subjects 8    7    NS 
Age (years) 35.5 ± 5.9 36.3 ± 7.4 NS 
Height (cm) 177.1 ± 9.4 180.9 ± 5.2 NS 
Weight (kg) 75.4 ± 9 84.1 ± 9.6 NS 
BMI (kg/m²) 24 ± 2.2 25.7 ± 2.4 NS 
HbA1c (%) 7.8 ± 0.9      
VO2max (ml/kg/min) 40.9 ± 3.6 44.5 ± 5 NS 
VO2max (l/min) 3.1 ± 0.5 3.7 ± 0.4 0.02 
T1D=type 1 diabetes, BMI=body mass index, HbA1c=glycosylated hemoglobin, 
VO2max=maximal oxygen uptake, NS=non-significant. 
 
3.2 Exercise protocol and determination of aerobic capacity  
 
Subjects performed a cycle spiroergometer test to evaluate maximal aerobic capacity 
(VO2max). Before the cycle spiroergometer test physician evaluated the subject’s 
suitability for maximal performance. The step incremental protocol was preceded by 
5 minutes rest while the subjects sat relaxed on a cycle ergometer followed by 5 minutes 
baseline unloaded cycling. The step incremental exercise protocol (40 W/3 min) was 
then initiated, and the subjects continued exercising until volitional fatigue. The test was 
monitored by an experienced physician. Ventilation and alveolar gas exchange were 
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measured breath-by-breath by a low-resistance turbine (Triple V, Jaeger Mijnhardt, 
Bunnik, Netherlands) and a mass spectrometer (AMIS 2000, Innovision, Odense, 
Denmark). To obtain VO2max values, gas delay determinations were performed to 
measure raw breath-by-breath data, and then alveolar gas exchange was calculated with 
the slightly modified algorithms of Beaver et al. (50). Moving averages of individual 
test data were calculated over 5 seconds periods to reduce breath-by-breath variability, 
and interpolated to obtain values second by second, after which a maximal oxygen 
uptake was determined as the highest value of a 60-second moving average window. 
 
3.3 Heart rate variability analysis 
 
Firstbeat heart rate monitor recorded subjects' RR 
intervals from the beginning of the cycle 
ergometer test for the next 24 hours (baseline 
measurements) or 48 hours (measurements after 
training intervention). The data from heart rate 
monitor were analyzed with both Firstbeat 
software and Kubios software. Before analyzing 
the data, it was manually checked and corrected 
for artefacts and ectopic beats in addition to 
automatic correction properties of Firstbeat 
Kuntovalmentaja -software. The data with more 
than 20 % of erroneous data was excluded.  
 
The analyzed periods were: six-hour period 
starting from one hour after maximal 
performance (day 1) and 4-hour period between 
00:00 and 4:00 or starting 30 minutes after 
reported bedtime (night). The third period was on 
the next day and it was at the same time of the Figure 1. Analyzed periods. 
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day as the first period (day 2) (Figure 1). Day 2 was analyzed only after training 
intervention due to shorter RRI data (24 hours) in baseline measurements. 
 
We used time and frequency domain analyses. In addition we used Poincare plot 
analysis and detrended fluctuation analysis (DFA) as nonlinear methods. In time 
domain analyses mean RRI (RR interval), SDNN (standard deviation of RR intervals), 
RMSSD (root mean square of successive differences) and pNN50 (proportion of 
number of successive intervals differing more than 50 ms) were analyzed. In frequency 
domain analysis Fast Fourier transformation (FFT) was used and very low frequency (0-
0.04 Hz), low frequency (0.04-0.15 Hz) and high frequency (0.15-0.4 Hz) powers were 
analyzed in absolute values and LF and HF also as normalized units. Also LF/HF ratio 
was calculated. We analyzed SD1 and SD2 by Poincare plot and alpha 1 by DFA. (4)  
 
3.4 Training intervention  
 
Part of the subjects underwent 6-12 months training intervention. After that, their 
aerobic capacity and HRV were measured again. The goals of the 6-12 months training 
intervention were agreed with the subjects and the results from the clinical and exercise 
tests were used to individualize exercise prescription. Both endurance and strength 
training were included in the exercise program. The training groups performed exercise 
sessions individually and as guided by the University Sports. The subjects also 
participated in other guided exercise sessions as a part of their exercise prescription, if 
they wished.  
 
3.5 Statistical analysis 
 
The R software (2.13.0) for statistical computing and PASW statistics 18 were used for 
statistical analysis. We excluded data with more than 20 % erroneous data thus the 
number of subjects varied between 11 and 13 in baseline measurements and between 4 
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and 7 in measurements after training intervention. Subjects varied in different analyses 
(day 1, night and day 2) due to more than 20 % erronous data in some subjects’ RRI-
data. The T-test was used for testing differences in aerobic capacity and HRV between 
type 1 diabetes patients and controls. Welch’s T-test was used for testing training 
intervention induced changes in HRV variables and aerobic capacity. Correlations were 
tested by Pearson’s correlation. Significance was defined as p<0,05. 
 
4 Results 
 
4.1 Aerobic capacity  
 
Type 1 diabetes patients had significantly lower VO2max than healthy controls (36.9 
ml/kg/min vs. 42.9 ml/kg/min, p=0.036) even though they were self-reported leisure-
time physical activity matched (Table 1). VO2max correlated significantly with leisure-
time physical activity in healthy controls (r=0.609, p=0.012) but not in type 1 diabetes 
patients (r=0.082, p=0.791) (Figure 2).  
 
Figure 2. Correlations between leisure-time physical activity and aerobic capacity. For 
healthy controls r=0.609, p=0.012. For type 1 diabetes patients r=0.082, p=0.791. 
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4.2 Heart rate variability 
 
There was not a significant difference in any of the studied HRV parameters between 
type 1 diabetes patients and healthy controls at day or night (Table 3). Mean RRI i.e. 
resting heart rate did not differ between groups in spite of the difference in VO2max. 
 
Mean RRI at day 1 correlated with leisure-time physical activity
 
in healthy controls 
(r=0.637, p=0.035) but not in type 1 diabetes patients (r=0.214, p=0.482) (Figure 3). 
Also LF/HF-ratio at day 1 correlated significantly with VO2max in healthy controls (r=-
0.711, p=0.014) but not in type 1 diabetes patients (r=0.272, p=0.369) (Figure 4). At 
day 1 glycosylated hemoglobin (HbA1c) in type 1 diabetes patients correlated 
significantly with SDNN (r=-0.645, p=0.023) (Figure 5), absolute VLF power (r=-
0.648, p=0.023) (Figure 6) and SD2 of Poincare plot (r=-0.646, p=0.023) (Figure 7). At 
night there were no correlations in either group between HRV and VO2max, LTPA, 
HbA1c or duration of diabetes. 
 
Figure 3. Correlations between leisure-time physical activity and mean RR interval at 
day 1. For healthy controls r=0.637, p=0.035. For type 1 diabetes patients r=0.214, 
p=0.482. 
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Figure 4. Correlations between aerobic capacity and LF/HF-ratio at day 1. For healthy 
controls r=-0.711, p=0.014. For type 1 diabetes patients r=0.272, p=0.369. 
 
 
Figure 5. Correlation between HbA1c and SDNN in type 1 diabetes patients at day 1. 
r=-0.645, p=0.023. 
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Figure 6. Correlation between HbA1c and absolute VLF power in type 1 diabetes 
patients at day 1. r=-0.648, p=0.023. 
 
 
Figure 7. Correlation between HbA1c and SD2 of Poincare plot in type 1 diabetes 
patients at day 1. r=-0.646, p=0.023. 
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4.3 Effects of training intervention on aerobic capacity and heart rate 
variability 
  
 
After training intervention there was not a significant difference in VO2max (ml/kg/min) 
or in HRV between type 1 diabetes patients and healthy controls who underwent 
training intervention. The difference in absolute VO2max persisted (3.1±0.5 l/min vs. 
3.7±0.4 l/min, p<0.05) (Table 2). There was a tendency toward higher LF/HF-ratio in 
type 1 diabetes patients at night (4.5±2.7 vs. 2.2±0.9, p=0.06) (Table 4). The change in 
VO2max and HRV was analyzed only in those subjects who underwent the training 
period. Training intervention induced a significant increase in VO2max both in type 1 
diabetes patients (+4.4 ml/kg/min, p<0.05) and in healthy controls (+3.4 ml/kg/min, 
p<0.05). Due to varying subjects in different analysis, statistically significant increase in 
VO2max in healthy controls was seen only in night analysis. 
 
The change in HRV after 6-12-months training-period was not statistically significant in 
type 1 diabetes patients or in healthy controls (Table 5). Mean RR interval at night was 
significantly increased in type 1 diabetes patients after training period meaning that 
their resting heart rate decreased. After training intervention there were no significant 
correlations between VO2max, HbA1c and HRV in type 1 diabetes patients or healthy 
controls who performed 6-12 months training period.
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Table 3. HRV in baseline measurements. Results are presented as mean ± standard deviation. 
  Day 1 Night 
  T1D (n=13) HC (n=11) p T1D (n=12) HC (n=13) p 
Mean RRI (ms) 752.0 ± 110.3 806.8 ± 110.7 0.24 1045.8 ± 135.6 1097.4 ± 140.3 0.36 
SDNN (ms) 108.8 ± 38.0 127.1 ± 47.2 0.30 97.0 ± 35.1 110.2 ± 38.1 0.38 
RMSSD (ms) 26.8 ± 12.4 35.0 ± 22.0 0.26 45.1 ± 15.2 55.4 ± 32.1 0.32 
pNN50 (%) 7.2 ± 6.7 11.8 ± 11.0 0.22 23.0 ± 12.1 26.0 ± 19.3 0.65 
Absolute VLF (ms²) 8048.5 ± 4954.0 11538.9 ± 9366.3 0.26 5579.5 ± 3541.2 7448.1 ± 4461.4 0.26 
Absolute LF (ms²) 1220.9 ± 782.6 1824.8 ± 1212.6 0.16 1606.3 ± 951.5 1940.1 ± 1535.2 0.52 
Absolute HF (ms²) 272.1 ± 228.6 556.9 ± 650.4 0.15 700.6 ± 388.9 1040.7 ± 1108.3 0.33 
LF power (n.u.) 82.7 ± 5.7 82.8 ± 9.8 0.98 69.5 ± 16.4 69.5 ± 9.3 1.00 
HF power (n.u.) 17.3 ± 5.7 17.2 ± 9.8 0.98 30.5 ± 16.4 30.5 ± 9.3 1.00 
LF/HF-ratio 5.6 ± 3.0 6.8 ± 4.4 0.44 3.2 ± 2.4 2.6 ± 1.2 0.41 
SD1 (Poincare) (ms) 18.9 ± 8.8 24.7 ± 15.5 0.26 31.9 ± 10.8 39.2 ± 22.7 0.32 
SD2 (Poincare) (ms) 152.6 ± 53.2 177.9 ± 65.3 0.31 133.0 ± 49.7 150.4 ± 50.1 0.39 
α1 (DFA) 1.5 ± 0.1 1.5 ± 0.2 0.97 1.2 ± 0.3 1.2 ± 0.2 0.98 
T1D=type 1 diabetes patients, HC= Healthy controls, RRI=RR interval, SDNN=standard deviation of RR intervals, RMSSD= the square root of 
the mean squared differences of successive RR intervals, pNN50=the percentage of number of successive intervals differing more than 50 ms, 
VLF=very low freguency, LF=low freguency, HF=high frequency, n.u.=normalized units, DFA=detrended fluctuation analysis. 
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Table 4. HRV in post-training measurements. Results are presented as mean ± standard deviation. 
  Day 1 Night Day 2 
  T1D (n=5) HC (n=6) P T1D (n=5) HC (n=7) p T1D (n=4) HC (n=6) p 
Mean RRI (ms) 780.6 ± 79.8 729.2 ± 100.0 0.38 1123.7 ± 133.2 1150.5 ± 183.1 0.79 877.1 ± 82.7 818.9 ± 118.6 0.42 
SDNN (ms) 99.6 ± 26.4 107.9 ± 34.2 0.67 94.9 ± 20.0 111.7 ± 44.6 0.46 115.8 ± 10.7 130.5 ± 33.0 0.42 
RMSSD (ms) 24.9 ± 8.0 27.9 ± 23.9 0.80 46.2 ± 13.3 61.3 ± 44.0 0.48 33.1 ± 10.3 37.7 ± 24.1 0.73 
pNN50 (%) 5.5 ± 5.3 7.7 ± 11.9 0.72 22.6 ± 15.6 30.2 ± 27.4 0.59 11.7 ± 8.5 14.4 ± 14.4 0.74 
Absolute power 
(VLF) 6405.3 ± 3365.6 8195.9 ± 5565.3 0.55 5066.9 ± 2298.3 7403.1 ± 5096.5 0.37 8284.1 ± 2144.1 10974.1 ± 5616.4 0.39 
Absolute power (LF) 1319.1 ± 608.1 1560.6 ± 1605.2 0.76 1912.1 ± 431.6 1905.4 ± 1504.7 0.99 1578.7 ± 419.1 1995.7 ± 1514.8 0.61 
Absolute power (HF) 222.2 ± 195.7 450.5 ± 727.5 0.52 660.4 ± 605.3 1329.9 ± 1794.5 0.45 366.6 ± 276.7 572.0 ± 684.4 0.59 
LF power (n.u.) 86.3 ± 7.2 85.6 ± 8.4 0.89 76.2 ± 15.0 66.1 ± 10.8 0.20 82.9 ± 9.7 82.4 ± 7.2 0.94 
HF power (n.u.) 13.7 ± 7.2 14.4 ± 8.4 0.89 23.8 ± 15.0 33.9 ± 10.8 0.20 17.1 ± 9.7 17.6 ± 7.2 0.94 
LF/HF-ratio 8.1 ± 4.4 7.6 ± 3.6 0.84 4.5 ± 2.7 2.2 ± 0.9 0.06 6.7 ± 4.6 5.5 ± 2.5 0.58 
SD1 (Poincare) (ms) 17.6 ± 5.7 19.7 ± 16.9 0.80 32.7 ± 9.4 43.4 ± 31.1 0.48 23.4 ± 7.3 26.6 ± 17.0 0.73 
SD2 (Poincare) (ms) 139.7 ± 37.4 151.0 ± 46.5 0.67 130.0 ± 27.8 150.6 ± 58.7 0.49 162.0 ± 14.9 182.3 ± 44.8 0.42 
α1 (DFA) 1.5 ± 0.1 1.5 ± 0.2 0.98 1.3 ± 0.2 1.2 ± 0.2 0.26 1.5 ± 0.2 1.5 ± 0.1 0.94 
T1D=type 1 diabetes patients, HC= Healthy controls, RRI=RR interval, SDNN=standard deviation of RR intervals, RMSSD= the square root of 
the mean squared differences of successive RR intervals, pNN50=the percentage of number of successive intervals differing more than 50 ms, 
VLF=very low freguency, LF=low freguency, HF=high frequency, n.u.=normalized units, DFA=detrended fluctuation analysis. 
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Table 5. Change in HRV in type 1 diabetes patients and healthy controls. 
  Day 1 Night 
  T1D (n=5) HC (n=7) T1D (n=5) HC (n=6) 
  MD  95 % CI p MD  95 % CI p MD  95 % CI p MD  95 % CI p 
Mean RRI (ms) 15.16 (-32.8-63.1)   0.43 -33.5 (-86.4-19.4)  0.16 110.6 (4.6-216.6) 0.04 55.0 (-18.3-128.4) 0.12 
SDNN (ms) -8.0 (-21.4-5.3) 0.17 -10.1 (-43.9-23.7)  0.48 -9.6 (-47.8-28.7) 0.53 2.7 (-17.8-23.2) 0.76 
RMSSD (ms) -0.9 (-5.1-3.3)   0.57 -2.6 (-7.1-1.9) 0.19 4.8 (-12.4-22.0) 0.48 2.6 (-8.2-13.5) 0.57 
pNN50 (%) -1.1 (-3.6-1.4)   0.29 -1.1 (-4.1-1.9) 0.39 3.3 (-12.9-19.4) 0.61 1.1 (-6.9-9.1) 0.75 
Absolute VLF (ms²) -1199.2 (-3168.4-770.1) 0.17 -2786.5 (-10749.8-5176.7) 0.41 -1936.0 (-5651.2-1779.2) 0.22 74.1 (-3791.3-3939.5) 0.96 
Absolute LF (ms²) 
-24.5 (-243.7-194.7) 0.77 -130.8 (-754.5-492.8) 0.61 170.4 (-993.9-1334.7) 0.71 -35.4 (-739.7-668.9) 0.91 
Absolute HF (ms²) 
-20.1 (-75.5-35.3)   0.37 -71.3 (-179.2-36.6) 0.15 110.7 (-406.9-628.3) 0.58 90.0 (-361.2-541.3)   0.64 
LF power (n.u.) 1.4 (-1.5-4.2)   0.26 0.0 (-3.4-3.5) 0.98 -1.5 (-9.3-6.4) 0.63 -2.7 (-12.3-6.8) 0.51 
HF power (n.u.) -1.4 (-4.2-1.5) 0.26 0.0 (-3.5-3.4) 0.98 1.5 (-6.4-9.3) 0.63 2.7 (-6.8-12.3) 0.51 
LF/HF-ratio 1.5 (-0.7-3.6)  0.13 -1.3 (-3.0-0.3) 0.08 0.1 (-1.3-1.5)  0.86 -0.5 (-1.8-0.9) 0.44 
SD1 (Poincare) (ms) -0.7 (-3.6-2.3)  0.57 -1.9 (-5.0-1.3) 0.19 3.4 (-8.7-15.6) 0.48 1.9 (-5.8-9.6) 0.57 
SD2 (Poincare) (ms) -11.4 (-30.3-7.7) 0.17 -14.3 (-62.3-33.8) 0.48 -14.8 (-68.5-39.0) 0.49 2.6 (-30.0-35.3) 0.85 
α1 (DFA) 0.01 (-0.09-0.07) 0.83 -0.02 (-0.04-0.01) 0.17 -0.04 (-0.16-0.07) 0.36 -0.02 (-0.18-0.13) 0.71 
T1D=type 1 diabetes patients, HC= Healthy controls, MD=mean difference, CI=confidence interval, RRI=RR interval, SDNN=standard 
deviation of RR intervals, RMSSD= the square root of the mean squared differences of successive RR intervals, pNN50=the percentage of 
number of successive intervals differing more than 50 ms, VLF=very low freguency, LF=low freguency, HF=high frequency, n.u.=normalized 
units, DFA=detrended fluctuation analysis. 
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5 Discussion 
 
The aim of this study was to examine if there is a difference in 48-hour heart rate 
variability (HRV) after incremental cycle ergometer test in type 1 diabetes patients and 
healthy controls and if the possible difference is related to diabetes and/or aerobic 
capacity. The main findings were as follows: Aerobic capacity (VO2max) was 
significantly lower in type 1 diabetes patients than in healthy controls. There was not a 
significant difference in HRV between these groups. Leisure-time physical activity 
correlated significantly with VO2max and mean RR interval during daytime in healthy 
controls but not in type 1 diabetes patients. Also, in healthy controls there was a 
correlation between VO2max and LF/HF-ratio at daytime. Glycosylated hemoglobin 
(HbA1c) in type 1 diabetes patients correlated significantly with SDNN, absolute VLF 
power and SD2 of Poincare plot at daytime. There were no significant correlations 
between aerobic capacity, leisure-time physical activity, glycosylated hemoglobin, 
duration of diabetes and heart rate variability at night in either group. 
 
In addition, part of the subjects performed 6-12 months training period and after that 
aerobic capacity and HRV were measured again. Training significantly increased 
VO2max in type 1 diabetes patients and healthy controls. The increase in aerobic capacity 
was higher in type 1 diabetes patients than in healthy controls. After training 
intervention there was not a significant difference in aerobic capacity or in HRV 
between type 1 diabetes patients and healthy controls who underwent this training 
intervention. In our study there was not a significant change in HRV in either of these 
training groups even though VO2max significantly increased. 
 
5.1 Aerobic capacity 
 
In our study aerobic capacity was significantly lower in type 1 diabetes patients than in 
healthy controls as it has been previously widely reported (41,42,44,45). Possible 
explanation can be independent effect of glycemic control on aerobic capacity.  It has 
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been reported that when comparing type 1 diabetic athletes with optimal glycemic 
control and with poor glycemic control, VO2max has been significantly higher in type 1 
diabetic athletes with optimal glycemic control (48). It has been suggested that in type 1 
diabetes patients with poor glycemic control cardiac pump function is impaired. 
Impairment is resulted from inability to reach age-determined maximal heart rate and 
from diastolic dysfunction leading to lower stroke volume. (51) Also pulmonary 
diffusion in chronically hyperglycemic type 1 diabetes patients seems to be reduced 
(52), but according one review the reduction is too modest to explain the lower aerobic 
capacity (51). 
 
In this same study population as in this study hemoglobin mass has been studied. This 
study suggests that difference in VO2max between type 1 diabetes patients can also be 
due to lower total hemoglobin mass and blood volume (43). Also active muscle 
deoxygenation has been studied in this same study population. During cycle ergometer 
test earlier tissue deoxygenation in leg muscles was found in type 1 diabetes patients 
suggesting lower cardiac output and/or impaired peripheral vascular function. (44) 
 
VO2max significantly correlated with leisure-time physical activity in healthy controls 
but not in type 1 diabetes patients. Leisure-time physical activity had also significant 
correlation with mean RR interval i.e. heart rate, but only in healthy controls. Leisure-
time physical activity includes all the exercise subjects usually have during the week, so 
it did not discriminate between light, moderate or heavy exercise and so there is 
possibility that type 1 diabetes patients’ training intensity could have been lower. Also, 
the leisure-time physical activity was self-reported so there is a slight possibility of 
reporting bias. In addition, in type 1 diabetes patients the variation in VO2max was 
smaller than in healthy controls and this could be a reason why there is not a significant 
correlation between leisure-time physical activity and aerobic capacity in type 1 
diabetes patients. 
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5.2 Heart rate variability 
 
To our knowledge, this was the first study researching HRV in type 1 diabetes patients 
during long-term recovery. There was not a significant difference in HRV between type 
1 diabetes patients and healthy controls during long-term recovery in spite of diabetes 
and difference in VO2max. We wanted to examine HRV in type 1 diabetes patients 
without diabetes-related complications so our type 1 diabetic subjects did not have 
autonomic neuropathy. Several previous studies which have reported a difference in 
HRV between type 1 diabetes patients and healthy controls have not excluded cardiac 
autonomic neuropathy (CAN) as we did (4,20,23,24). In aforementioned studies HRV 
was studied during rest, during autonomic function tests and during daily activities. One 
study reported type 1 diabetes patients without clinical evidence of CAN to have 
significantly lower HRV than healthy controls. In that study HRV was examined over 
60 minutes period in resting conditions. (21) One study did not find a significant 
difference in HRV between type 1 diabetes patients without CAN and healthy controls. 
HRV was recorded for 24 hours during subjects’ daily activities. (25) Our study 
population did not have CAN and HRV was recorded during their daily activities so our 
result is consistent with last-mentioned study but our analyzed periods were four or six 
hours. However, it cannot be overemphasized that this was the first study to examine 
HRV in type 1 diabetes patients during long-term recovery so our results are not 
directly comparable with previous studies. 
 
In our study population ANS function has been previously evaluated by HRV, systolic 
blood pressure variability and baroreflex sensitivity at rest and during handgrip and 
active standing tests. There were no differences at rest but during maneuvers alpha1 
responses in DFA were smaller in type 1 diabetes patients. (28) In this study maximal 
performance did not help to show up possible autonomic dysfunction in type 1 diabetes 
patients studied by HRV during 48-hour recovery. A few studies suggest that single 
bout of exercise reduces HRV parameters reflecting parasympathetic tone for next 24 
hours so maximal performance is an interesting maneuver to affect HRV (9,37,38). This 
also means that we cannot make conclusions of our subjects’ normal long-term HRV 
based on HRV after maximal performance.   
21 
 
 
One review suggests that among time domain measures of HRV, pNN50 < 3% and 
RMSSD < 25 milliseconds are used to assess impairment of vagal activity; SDNN 
< 100 milliseconds are considered as a rough index of abnormal sympathetic outflow 
(2). In our study, only in day 1 analysis after training intervention type 1 diabetes 
patients had RMSSD lower than 25 milliseconds. In type 1 diabetes patients in three of 
five analyses SDNN was lower than 100 milliseconds. Otherwise these parameters were 
normal. Based on these values our type 1 diabetes patients did not have an impairment 
of vagal activity. It is controversial if there is abnormal sympathetic outflow in type 1 
diabetes patients because SDNN varied in different analyses being both under and over 
100 milliseconds. In healthy controls there was not abnormality in vagal or sympathetic 
activity based on time-domain measurements. However, there is not official consensus 
for normal HRV values or the length of HRV data so it is hard to make conclusions 
based only on these time domain measures. 
 
In type 1 diabetes patients HbA1c correlated with SDNN, absolute VLF power and SD2 
of Poincare plot so that lower HbA1c correlated with higher HRV parameters. SDNN 
represents overall HRV, whereas the role of VLF power remains unclear. (2) SD2 
represents long-term heart rate variability and it seems to correlate with LF power and 
LF/HF-ratio (53-55). This might indicate that in our subjects higher HbA1c reflecting 
chronically higher blood glucose levels could have slightly reduced their HRV and 
disturbed their sympathovagal balance. The correlation was not found between VO2max 
and HRV, this could mean that long-term blood glucose level has stronger effect on 
overall HRV than aerobic capacity has. The variation in HbA1c was not higher than in 
VO2max so this does not explain why there was a significant correlation between HbA1c 
and HRV and not between VO2max and HRV. 
 
Type 1 diabetes usually causes very notable symptoms (polyuria, polydipsia, 
polyphagia and losing weight, in severe cases ketoacidosis) and because of that 
diagnosis is usually set at early phase of the disease whereas in type 2 diabetes the delay 
to diagnosis can be quite long. The long-term goal of insulin treatment is the prevention 
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of chronic complications by maintaining blood glucose levels as close to normal as 
possible. Long-term blood glucose levels can be monitored by HbA1c. HbA1c-goal is 
usually under 7% without severe hypoglycemias. Usually HbA1c-goal can be defined to 
level 7.0 – 7.5%. Our type 1 diabetes patients’ mean HbA1c was 7.2 – 7.8% so 
glycemic control was fairly good. Nowadays insulin therapy is based on multiple daily 
injections (long-lasting and short- or rapid-acting insulin) or insulin pump and this way 
it mimics normal insulin secretion by pancreas. (56) That was also the case in our type 1 
diabetes patients. Long-term blood glucose levels as well as genetic factors affect 
development of autonomic neuropathy, that is, in same blood glucose levels some 
individuals develop autonomic neuropathy when some individuals do not (Camilla 
Schalin-Jäntti, personal communication, 14.1.2013).  
 
In healthy controls there was a significant correlation between VO2max and LF/HF-ratio 
at daytime so that higher aerobic capacity correlated with lower LF/HF-ratio. LF/HF-
ratio reflects sympathovagal balance. This means that healthy subjects with higher 
aerobic capacity had increased parasympathetic or decreased sympathetic tone. As 
mentioned previously, regular aerobic exercise increases vagal tone (30) so this 
correlation can indicate enhanced vagal tone in healthy subjects with higher aerobic 
capacity. It is possible that chronically higher blood glucose levels in type 1 diabetes 
patients disturbs their sympathovagal balance and good aerobic capacity cannot 
compensate that. One study also reported that HF power significantly decreases with 
increasing duration of diabetes so this can increase type 1 diabetes patients’ LF/HF-ratio 
(25). 
 
Probably differences in HRV during recovery could have been seen if type 1 diabetes 
patients had had autonomic neuropathy. We studied type 1 diabetes patients without 
remarkable complications and fair glycemic control. Some HRV parameters reflecting 
parasympathetic tone (RMSSD, pNN50) were lower in type 1 diabetes patients than in 
healthy controls even though the difference was not significant. It could be possible that 
with more subjects the result would have been statistically significant. Number of 
subjects was low especially in analyses after training intervention as well as in analyses 
comparing baseline and post-training intervention HRV and this weakens the statistical 
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power. HRV during recovery would be interesting to study with more subjects to figure 
out if there could be a statistically significant difference in HRV. Also studying HRV 
during long-term recovery and effect of training intervention would be interesting to 
study in subjects with known reduced HRV to assess the effect of exercise on reduced 
HRV during recovery. 
 
5.3 Effects of training intervention on aerobic capacity and heart rate 
variability 
 
Training increased aerobic capacity both in type 1 diabetes patients and healthy 
controls. In our study training did not induce a significant change in HRV either in type 
1 diabetes patients or healthy controls who performed training intervention in spite of 
significant increase in aerobic capacity. One study reported that aerobic exercise 
increases HRV (49). There is also study in which six year training intervention had no 
effect on heart rate variability (57) but it must be taken into consideration that HRV 
declines with age (2). In one review the effect of training on HRV was found to be 
controversial. The suggested explanation was that subject’s baseline HRV has an effect 
on change in HRV i.e. if the baseline HRV is high the increase in HRV is small and 
vice versa. (30) According to previous studies it is controversial whether there is 
correlation between aerobic capacity and HRV so that higher VO2max is correlated with 
higher HRV (35,58). It is also reported that exercise intensity has an effect on nighttime 
HRV. In recreational endurance runners moderate- and high-intensity training increased 
nighttime vagal activity studied by HRV but low-intensity training did not. (59) 
 
5.4 Study design 
 
Subjects performed their cycle ergometer test in different times of day thus the analyzed 
RRI periods were also in different times of day. Accordingly, we could not take into 
account circadian variation in HRV when analyzing daytime HRV (7). Also there was a 
slight difference how much time has passed after maximal performance when analyzing 
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HRV at night. This could have affected HRV results. However, the analyzed periods 
were at daytime and during sleep in every subject. The conditions were not the same in 
different subjects while recording the RR interval data because they continued their 
normal activities after maximal performance. This should not have affected HRV based 
on the study reporting that physical activity can affect short-term HRV studied by 
Poincare plot but not long-term HRV (SDNN, VLF power and SD2) (60). 
 
The manual correction i.e. removing artefacts and ectopic beats should not have had a 
significant effect on time-domain analysis even though it caused variation in the length 
of RRI data.  When comparing time-domain analysis results, 20 % removal of RRI data 
should not affect these results (Esa Hynynen, personal communication, 21.3.2012). 
 
6 Conclusion 
 
In this study there was a significant difference in VO2max even though type 1 diabetes 
patients and healthy controls were self-reported leisure-time physical activity matched. 
However, this did not reflect as differences in HRV during the next 48 hours after the 
incremental exercise test between type 1 diabetes patients and healthy controls. Lower 
aerobic capacity in type 1 diabetes patients has been previously widely reported. Six to 
twelve months training period increased aerobic capacity both in type 1 diabetes 
patients and healthy controls but it did not induce changes in HRV. Even though there 
was not a sign of impaired autonomic function in type 1 diabetes patients, regular 
exercise is recommended both type 1 diabetes patients as well as healthy controls to 
prevent cardiovascular diseases and to maintain normal weight. Intensive treatment of 
type 1 diabetes is proven to reduce complications (61) and regular exercise has a 
positive effect on glycemic control. Maximal performance is an interesting maneuver to 
affect HRV and HRV during long-term recovery in type 1 diabetes patients with known 
reduced HRV would be an interesting field of research.  
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